Edition:
United States

Leap Therapeutics Inc (LPTX.OQ)

LPTX.OQ on NASDAQ Stock Exchange Global Market

6.77USD
15 Dec 2017
Change (% chg)

$0.10 (+1.50%)
Prev Close
$6.67
Open
$6.66
Day's High
$6.78
Day's Low
$6.65
Volume
5,647
Avg. Vol
8,984
52-wk High
$10.10
52-wk Low
$4.94

Chart for

About

Leap Therapeutics, Inc., formerly HealthCare Pharmaceuticals, Inc., is a clinical-stage biopharmaceutical company. The Company engages in acquiring and developing therapeutics in cancer biology. Its lead product candidates for use in clinical trials include TRX518 and DKN-01. DKN-01 is a monoclonal antibody targeting Dickkopf-re... (more)

Overall

Beta: --
Market Cap(Mil.): $63.61
Shares Outstanding(Mil.): 9.40
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 198.20 16.04
EPS (TTM): -- -- --
ROI: -- -11.76 34.69
ROE: -- -36.72 15.46

BRIEF-Leap Therapeutics Files For Resale Of Up To 3.73 Mln Shares Of Co's Common Stock By Selling Stockholders

* LEAP THERAPEUTICS INC FILES FOR RESALE OF UP TO 3.73 MILLION SHARES OF CO'S COMMON STOCK BY THE SELLING STOCKHOLDERS - SEC FILING Source text: (http://bit.ly/2jdjIfs) Further company coverage:

Dec 08 2017

BRIEF-Eli Lilly And Co reports 17.5 pct passive stake in Leap Therapeutics ‍​as of Nov 14

* Eli Lilly And Co reports 17.5 percent passive stake in Leap Therapeutics Inc‍​ ‍​as of November 14 - SEC Filing Source text: (http://bit.ly/2BcO2L7) Further company coverage:

Nov 22 2017

BRIEF-Leap Therapeutics announces $18 million private placement offering

* Upon closing of transaction, leap will sell 2.96 million shares of unregistered common stock​

Nov 15 2017

BRIEF-Leap Therapeutics qtrly loss per share $0.73

* Leap Therapeutics reports third quarter 2017 financial results and announces first patient dosed with DKN-01 and Keytruda® (pembrolizumab) in esophagogastric cancer trial

Nov 13 2017

BRIEF-Leap Therapeutics announces collaboration with EORTC

* Leap Therapeutics announces collaboration with EORTC to evaluate DKN-01 in combination with PD-l1 cancer immunotherapy and chemotherapy in esophagogastric and biliary tract cancers

Sep 08 2017

BRIEF-Leap Therapeutics says Q2 loss per share $0.74

* Q2 loss per share $0.74 - SEC filing Source text for Eikon: Further company coverage:

Aug 11 2017

BRIEF-Leap Therapeutics Q2 net loss $6.9 mln vs $7.5 mln, a year earlier

* Leap therapeutics reports second quarter 2017 financial results

Aug 11 2017

BRIEF-Leap Therapeutics says Merck will sponsor and fund initial trials of their combo drug study

* Leap Therapeutics - under agreement with unit of Merck, Co to sponsor and fund phase i/ii clinical trials of combination of dkn-01 and keytruda(reg)

Jun 21 2017

BRIEF-Leap Therapeutics announces collaboration with Merck

* Leap therapeutics announces collaboration with merck to evaluate keytruda® (pembrolizumab) in combination with dkn-01 in esophagogastric cancer

Jun 21 2017

Earnings vs. Estimates